Last update 08 Mar 2025
Suzhou Yasheng Pharmaceutical Co., Ltd.

Suzhou Yasheng Pharmaceutical Co., Ltd.

Private Company | Subsidiary Company|
2016|
Jiangsu Sheng, China

Overview

Tags

Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
Small molecule drug
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms9
Hemic and Lymphatic Diseases6
Immune System Diseases6
Endocrinology and Metabolic Disease5
Nervous System Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug8
Chemical drugs1
Top 5 TargetCount
IAP(Inhibitors of apoptosis (IAP) protein family)1
ALK x FAK x ROS11
XIAP x cIAP1/cIAP21
KRAS G12D(GTPase KRas G12D)1
Bcl-2(Apoptosis regulator Bcl-2)1

Related

9
Drugs associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Olverembatinib
Target
Bcr-Abl T315I x c-Kit
Mechanism
Bcr-Abl T315I inhibitors [+1]
Active Org.
Ascentage Pharma Group, Inc. [+3]
Originator Org.
Guangzhou Shunjian Biomedical Technology Co., Ltd.Guangzhou Shunjian Biomedical Technology Co., Ltd.
Active Indication
Aggressive-Phase Chronic Myelocytic Leukemia [+11]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date24 Nov 2021
Lisaftoclax
Target
Bcl-2
Mechanism
Bcl-2 inhibitors
Active Org.
Ascentage Pharma Group, Inc. [+3]
Originator Org.
Jiangsu Yasheng Pharmaceutical Development Co. Ltd.Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Active Indication
Chronic Lymphocytic Leukemia [+28]
Inactive Indication
Advanced Malignant Solid Neoplasm [+2]
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
APG-2449
Target
ALK x FAK x ROS1
Mechanism
ALK inhibitors [+2]
Active Org.
Suzhou Yasheng Pharmaceutical Co., Ltd.Suzhou Yasheng Pharmaceutical Co., Ltd. [+3]
Originator Org.
Jiangsu Yasheng Pharmaceutical Development Co. Ltd.Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Active Indication
Non-Small Cell Lung Cancer [+6]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
46
Clinical Trials associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
CTR20243841
/ RecruitingPhase 3
APG-2575 (Lisaftoclax）联合阿扎胞苷(AZA)治疗新诊断的中高危骨髓增生异常综合征患者的一项国际多中心、随机、双盲、安慰剂对照的关键性注册临床3期研究(GLORA–4)
[Translation] An international, multicenter, randomized, double-blind, placebo-controlled, pivotal Phase 3 registration study of APG-2575 (lisaftoclax) in combination with azacitidine (AZA) in patients with newly diagnosed intermediate- and high-risk myelodysplastic syndrome (GLORA-4)
CTR20244272
/ RecruitingPhase 1
APG-2449 单药或与抗癌药物联合在铂耐药复发卵巢癌或晚期实体瘤患者中的安全性、耐受性、药代动力学和药效学的I期研究
[Translation] A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APG-2449, Alone or in Combination with Anticancer Drugs, in Patients with Platinum-Resistant Recurrent Ovarian Cancer or Advanced Solid Tumors
CTR20243842
/ RecruitingPhase 3
奥雷巴替尼治疗SDH缺陷型胃肠道间质瘤的单臂关键性注册Ⅲ期临床研究（POLARIS-3）
[Translation] A single-arm pivotal registration phase III clinical study of orebactinib in the treatment of SDH-deficient gastrointestinal stromal tumors (POLARIS-3)
100 Clinical Results associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Suzhou Yasheng Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
2
2
Phase 1
Phase 2
3
1
NDA/BLA
Approved
1
1
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free